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Abstract
Cellular and nuclear uptake of [125I]tri-iodothyronine (T3)
and [125I]triiodothyroacetic acid (Triac) were compared in
cardiomyocytes of 2–3 day old rats, and the effect of
thyroid hormone analogs on cellular T3 uptake was
measured. Cells (5–10105 per well) were cultured in
DMEM–M199 with 5% horse serum and 5% FCS.
Incubations were performed for from 15 min to 24 h at
37 C in the same medium, 0·5% BSA and [125I]T3
(100 pM), or [125I]Triac (240 pM). Expressed as % dose,
T3 uptake was five times Triac uptake, but expressed as
fmol/pM free hormone, Triac uptake was at least 30%
(P<0·001) greater than T3 uptake, whereas the relative
nuclear binding of the two tracers was comparable. The
15 min uptake of [125I]T3 was competitively inhibited
by 10 µM unlabeled T3 (45–52%; P<0·001) or 3,3-
diiodothyronine (T2) (52%; P<0·001), and to a smaller
extent by thyroxine (T4) (27%; 0·05<P<0·1). In contrast,
10 µM 3,5-T2, Triac, or tetraiodothyroacetic acid (Tetrac)
did not affect T3 uptake after 15 min or after 24 h.
Diiodothyropropionic acid (DITPA) (10 µM) reduced
15-min T3 uptake by about 24% (P<0·05), but it had a
greater effect after 4 h (56%; P<0·001). Exposure to
10 nM DITPA during culture reduced cellular T3 uptake,
as did 10 nM T3, suggesting down-regulation of the
plasma membrane T3 transporters. We conclude that i)
Triac is taken up by cardiomyocytes; ii) 3,3-T2 and, to a
lesser extent, DITPA and T4 interfere with plasma mem-
brane transport of T3, whereas 3,5-T2, Triac, or Tetrac do
not; iii) the transport mechanism for Triac is probably
different from that for T3.
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Introduction
Thyroid hormone induces an increase in cardiac contrac-
tility and frequency, resulting in a greater cardiac output
(Polikar et al. 1993, Toft & Boon 2000, Klein & Ojamaa
2001), and a proportional change in energy turnover
(Clausen et al. 1991). Thyroid hormone also induces
relaxation of vascular smooth muscle (Ojamaa et al. 1996),
and it is very effective in reducing serum cholesterol (Staels
et al. 1990). Recently, the concept has been discussed that
initiation of thyroxine (T4) replacement therapy may pre-
cipitate angina pectoris (Gammage & Franklyn 1997),
whereas increased serum triiodothyronine (T3) at the time
of admission to hospital is associated with a greater risk for
the development of myocardial ischemia (Peters et al.
2000). This underscores the importance of developing
thyromimetic compounds with lipid-decreasing activity,
without cardiovascular and thermogenic effects (Boyd &
Oliver 1960, Underwood et al. 1986, Stephan et al. 1996,
Ichikawa et al. 2000, Trost et al. 2000).
Patients undergoing coronary bypass surgery (Holland
et al. 1991, Klemperer et al. 1995) and patients with
congestive heart failure (Hamilton 1993, Hamilton &
Stevenson 1996) may show typical changes in serum
thyroid hormone parameters – low serum T3, high serum
reverse T3 and normal T4 and thyrotropin (TSH) concen-
trations – known as the euthyroid sick syndrome (Docter
et al. 1993). Whether or not this condition should be
treated remains a matter of debate (Klemperer et al. 1995,
Utiger 1995, Camacho & Dwarkanathan 1999). How-
ever, during the past 5–10 years, clinical studies have
explored the possibility of improving heart function using
treatment with T3 or T4 (Moruzzi et al. 1996, Chowdhury
et al. 1999, Mullis-Jansson et al. 1999), both in children
with congenital heart disease and in elderly patients with
congestive heart failure. To date, the thyroid hormone
analog, diiodothyropropionic acid (DITPA), which poss-
ibly has a greater effect on cardiac contractility than on
frequency, has been applied in animal studies (Pennock
et al. 1993, 2000, Morkin et al. 1996, Spooner et al. 1999).
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With the purpose of suppressing thyrotropin (TSH)
secretion in patients with thyroid cancer (Pujol et al.
2000), triiodothyroacetic acid (Triac) has been tested
for specificity at the pituitary and the peripheral level
(Beck-Peccoz et al. 1988, Sherman & Ladenson 1992,
Everts et al. 1994, Sherman et al. 1997). In addition,
tetraiodothyroacetic acid (Tetrac) was more potent than T4
in reducing TSH release in isolated pituitary cells (Everts
et al. 1995) and in hypothyroid rats (Lameloise et al. 2001),
but it was less efficient in inducing cardiac hypertrophy
(Lameloise et al. 2001). Recent work on mitochondria
indicates that T3 metabolites such as 3,5-diiodothyronine
(3,5-T2) may have thermogenic effects (Goglia et al.
1999). Finally, several studies have demonstrated acute
effects of T3 (Davis & Davis 1993) and 3,5-T2 (Huang
et al. 1999) on the heart, in particular on ion channels.
In view of the significance of plasma membrane
transport for the bioavailability of thyroid hormones
(Hennemann et al. 1998, 2001), and the possible existence
of different transport systems in different tissues (Kragie
1994, Everts et al. 1996a), we have previously explored the
thyroid hormone transport system in the heart (Everts et al.
1996b, Van der Putten et al. 2001, Verhoeven et al. 2001).
In the present study we continued this work by comparing
the uptake of [125I]T3 with that of [
125I]Triac in neonatal
rat cardiomyocytes. Furthermore, we tested the effects of
T4, the analog DITPA, and the metabolites 3,3-T2,
3,5-T2, Triac and Tetrac on the uptake of [
125I]T3.
Materials and Methods
Animals
All experiments were performed using 2–3-day-old Wistar
rats of both sexes, obtained from laboratory stock. Rats
were killed by decapitation, and hearts were quickly
dissected and processed as described below, to isolate
cardiomyocytes.
Cell culture
Primary cultures of neonatal rat cardiomyocytes were
prepared as described in detail previously (Blondel et al.
1971), with some modifications (Van Heugten et al.1994,
Everts et al. 1996b, Verhoeven et al. 2001). In brief, hearts
were cut for 1 min and dissociated with 0·1% trypsin for
10 min at 33 C. Cells from the first treatment with
trypsin were decanted and discarded, and the remaining
tissue was further digested with fresh enzyme and
decanted. DMEM with medium 199 (M199) (4:1), 5%
FCS, 5% horse serum and 2% penicillin/streptomycin was
then added to the suspended cells. This procedure was
repeated seven times until all tissue was dissociated.
Deoxyribonuclease (20 U/ml) was added, and the remain-
ing tissue from the last step, together with the trypsinized
cells, was centrifuged (100 g) for 5 min. The supernatant
was discarded, and the cells were resuspended in 30 ml
DMEM–M199 with 5% FCS, 5% horse serum, and 2%
penicillin/streptomycin. The cell suspension was passed
through nylon mesh, and the dispersed cells were pre-
plated (Blondel et al. 1971) into 250 ml culture flasks for
60 min (37 C, 5% CO2) to remove fibroblasts. After this
procedure, the preparation consists of more than 90%
cardiomyocytes (Van Heugten et al. 1994). Cells of the
enriched cardiomyocyte fraction were plated into 48-well
culture dishes at subconfluent density (5105 cells/well)
in 1-ml volumes of DMEM–M199 with 5% FCS–5%
horse serum–2% penicillin/streptomycin, and in some
cases at a density of 106 cells/well in 2-ml volumes in
24-well culture dishes.
The cells were incubated in a humidified 5% CO2
atmosphere at 37 C for 1 day. After 1 day, the cells
revealed spontaneous and synchronous beating, and the
medium was replaced by the original culture medium.
Experiments were routinely performed after 5 days. In a
series of experiments, the cultured cells were exposed to
10 nM T3 or DITPA from the start of culture.
Although culturing cardiomyocytes in the presence of
serum may result in proliferation of contaminating fibro-
blasts that also show thyroid hormone transport (Docter
et al. 1987), we have previously shown that uptake of
thyroid hormones is comparable in cardiomyocytes cul-
tured for 5 days in absence or presence of serum (Everts
et al. 1996b, Verhoeven et al. 2001). Moreover, the uptake
of [125I]T3, expressed per µg protein, is more than 10-fold
greater in cardiomyocytes than in cardiac fibroblasts (S M
van der Heide, personal communication).
Cellular uptake of [125I]T3 and [
125I]Triac
The incubation medium was identical to the culture
medium, except that serum was replaced by 0·5% BSA for
measurements of [125I]T3 or [
125I]Triac uptake (Everts
et al. 1994, 1996b). Cells were preincubated (0·5 ml) for
30 min and incubated (0·25 ml) for from 15 min to 24 h at
37 C without or with 10 µM unlabeled T3, Triac, Tetrac,
3,3-T2, 3,5-T2, or 1 nM–10 µM DITPA, T3, T4 or Triac,
and in all cases [125I]T3 (100 000 c.p.m.; 100 pM) or
[125I]Triac (200 000 c.p.m.; 240 pM).
After incubation, the medium was removed and the
cells were washed with 1 ml ice-cold saline to remove
tracer not bound to the cells. This washing procedure
proved to be sufficient (Verhoeven et al. 2001). Cells were
dissolved in 1 ml 0·1 M NaOH and counted for iodine-
125 activity in a 16-channel gamma-counter (NE 1600,
Nuclear Enterprises, Edinburgh, UK). The amount of
[125I]T3 or [
125I]Triac taken up was expressed as a per-
centage of the added radioactivity (percentage of the dose).
The same procedure was applied to incubations without
cells (blanks). All results were corrected for the amount of
radioactivity recovered from the wells without cells.
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Nuclear [125I]T3 and [
125I]Triac binding
Cells were cultured at a density of 106 cells/well in
24-well culture dishes as described above. Preincubation
(30 min) and incubation (2 h) were performed at 37 C in
a volume of 0·5 ml, and [125I]T3 (200 000 c.p.m.; 100 pM)
or [125I]Triac (500 000 c.p.m.; 300 pM) during incu-
bation. Unlabeled T3 or Triac (both 10 µM) were present
only during incubation. After incubation, cells were
washed once with 2 ml ice-cold saline. The cells were
scraped from the wells with a rubber policeman in 1 ml
PBS (on ice) and the wells were washed with 0·5 ml PBS.
These two aliquots were combined and centrifuged (300 g
at 4 C for 7 min) and the cell pellet counted (30 s) and
solubilized in 1 ml PBS containing 0·5% Triton X-100
(Everts et al. 1996b, Verhoeven et al. 2001). After 2 min of
continuous vortexing, nuclei were spun down (900 g at
4 C for 5 min) and washed once with 1 ml PBS contain-
ing 0·5% Triton X-100. The nuclear pellets were counted
for 5 min and frozen for determination of DNA.
Free hormone concentrations
Calculation of the free hormone concentration was based
on determination of the free fraction by equilibrium
dialysis (Sterling & Brenner 1966). As shown previously
(Everts et al. 1994), the free fractions of T3 and Triac in
medium with 0·5% BSA were 3·450·19% (n=8) and
0·410·03% (n=5) respectively – a ninefold difference.
In the present study, the free T3 fraction was not changed
by the addition of 10 µM unlabeled T3, 3,3-T2, 3,5-T2,
Triac or Tetrac, and only slightly by 10 µM T4 (4·21%;
n=2). Upon addition of 0, 1 nM, 10 nM, 100 nM, 1 µM
or 10 µM DITPA, the free T3 fraction also showed a slight
increase: from 3·220·08% (n=5) to 3·61% (n=2),
3·49% (n=2), 3·45% (n=2), 3·78% (n=2) and 4·36
0·06% (n=3) respectively. The free Triac fraction was
0·380·02% (n=6), and did not change with 10 µM
unlabeled Triac.
DNA and protein determinations
DNA content was determined using a fluorimetric
method (Downs & Wilfinger 1983). The cellular protein
content was determined with the Bio-Rad Protein
Assay-Kit (Bio-Rad, Munich, Germany). Cells plated at a
density of 5105 cells/well contained about 0·1 mg
protein/well after 5 days of culture.
Chemicals and isotopes
All reagents used for cell isolation and cell culture were
obtained from Gibco Europe (Breda, The Netherlands),
with the exception of trypsin and deoxyribonuclease
(Boehringer, Mannheim, Germany). Culture dishes (48
and 24 wells) were obtained from Costar (Cambridge,
MA, USA). All iodothyronines, 3,5-diiodothyroacetic acid
(3,5-Diac), Triac, and Tetrac were obtained from
Henning Berlin (Berlin, Germany). BSA (fraction V)
and DITPA were purchased from Sigma Chemical Co.
(St Louis, MO, USA). [3-125I]T3 (3070 µCi/µg) was
purchased from Amersham International (Aylesbury,
Bucks, UK). [3-125I]Triac (2730 µCi/µg) was prepared
from Na125I and 3,5-Diac using the chloramine-T
method (Rutgers et al. 1989). Sephadex LH-20 was from
Pharmacia (Uppsala, Sweden). All other reagents were of
the highest purity available.
Calculations and statistics
On the basis of the free hormone fractions in the incu-
bation buffer with 0·5% BSA, the chemical concentration
of T3 (100 pM) or Triac (240 pM) in the buffer, and the
incubation volume, the counts per minute (percentage
added dose) were converted to fmol/pM free hormone. In
case the free hormone fraction was unknown – for
example in the cellular pellet and the nuclei (Table 1) –
data were only expressed as percentage of the added
radioactivity.
The statistical significance of any of the tested com-
pounds on [125I]T3 or [
125I]Triac uptake was evaluated by
Student’s t-test or by one-way analysis of variance and
Bonferroni’s test for multiple comparisons. P<0·05 was
regarded as statistically significant.
Results
Comparison of [125I]T3 and [
125I]Triac uptake
Time-course of cellular uptake Figure 1 shows the
time-course of [125I]T3 uptake () compared with that of
[125I]Triac () in cardiomyocytes, expressed as percent-
age of the dose (Fig. 1A) and as fmol/pM free hormone
(Fig. 1B). Both uptakes showed a steep phase up to 1 h of
incubation. Between 1 and 4 h of incubation, [125I]Triac
uptake reached equilibrium, whereas [125I]T3 uptake
showed a further increase. As can be seen in Fig. 1A,
[125I]T3 uptake was fivefold greater than that of
[125I]Triac, when expressed as percentage of the dose.
However, when expressed per pM free hormone
(Fig. 1B), the uptake of [125I]Triac was 30% greater than
that of [125I]T3.The free fractions of the two hormones in
buffer with 0·5% BSA were 3·5% for [125I]T3 and 0·4% for
[125I]Triac – a ninefold difference.
Nuclear binding To assess nuclear binding of T3 and
Triac, cardiomyocytes were preincubated for 30 min, and
incubated for 2 h with [125I]T3 or [
125I]Triac in the
absence or presence of 10 µM unlabeled T3 or Triac
(Table 1). Again, cellular uptake expressed as percentage
of the dose of [125I]T3 was fivefold greater than that of
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[125I]Triac. Incubation with 10 µM unlabeled T3 or Triac
inhibited cellular binding of [125I]T3 and [
125I]Triac, but
this effect was smaller than the inhibition of nuclear
binding: 19% compared with 72% for T3, and 34%
compared with 60% for Triac. The DNA contents of the
nuclear pellets in the absence or presence of 10 µM of the
unlabeled hormone were the same.
Effect of DITPA T3 uptake was also measured over a
4-h incubation period in the absence or presence of 10 µM
DITPA (Fig. 2). Results are expressed as fmol/pM free T3.
At incubation times 15 min, 1 h and 4 h, the presence of
10 µM DITPA reduced [125I]T3 uptake by 28%, 45% and
56% (all n=6; P<0·05) respectively.
Plasma membrane transport of [125]T3
Effects of T3, T4, Triac, DITPA, Tetrac 3,3-T2,
and 3,5-T2 Figure 3 shows the competitive effects of
increasing concentrations of unlabeled T3, T4, Triac and
Figure 1 Time-course of uptake of [125I]T3 () and [
125I]Triac ()
in neonatal rat cardiomyocytes expressed (A) as % dose and (B) as
fmol/pM free hormone. Cardiomyocytes were cultured for 5 days
at a density of 500 000 cells/well. Thereafter, culture medium was
removed and cells were preincubated for 30 min in incubation
medium with 0·5% BSA, followed by incubation in the same
medium with [125I]T3 (100 000 c.p.m./well) or [
125I]Triac
(200 000 c.p.m./well) for periods of 15 min–4 h. Data represent
meanS.E. of six observations from two independent experiments.
Table 1 Cellular and nuclear uptake of [125l] T3 and [
125I]Triac in cultured rat cardiomyocytes
[125I]T3 or [
125I]Triac activity (% dose)
Cell pellet (A) Nuclear pellet (B) (B/A)100% DNA content (ng)
Experimental conditions
[125I]T3 (5) 2·200·25 0·180·04 10·22·4 904118
+10 M T3 (6) 1·780·13 0·050·01 3·10·9 1122110
[125I]Triac (6) 0·410·03 0·050·01 11·13·0 1394163
+10 M Triac (6) 0·270·01 0·020·00 5·60·9 1570182
Data show meanS.E. of triplicate observations from two experiments. Cardiomyocytes were prepared from 2-day-old rats, and cultured for 1 day in 24-well
dishes in DMEM–M199–5% FCS–5% horse serum at a density of about 106 cells/well. After 1 day, the culture medium was changed and culture was
continued for 4 days. Cells were incubated at 37 C for 2 h with [125IT3 (200 000 c.p.m.) or [
125I]Triac (500 000 c.p.m.) in medium with 0·5% BSA. Cells were
scraped from the wells in PBS, centrifuged and the cell pellet (A) counted. The nuclear pellet (B) was obtained after treatment with Triton X-100. The third
column shows nuclear [125I]T3 or [
125I]Triac uptake relative to cellular [125I]T3 or [
125I]Triac uptake. The fourth column represents DNA content of the nuclear
pellet.
Figure 2 Time-course of the effect of 10 M DITPA on the uptake
of [125I]T3 in cardiomyocytes. Cells were cultured, preincubated
and incubated as described in the legend to Fig. 1, with 10 M
DITPA present during incubation. Data are expressed as fmol/pM
free T3, and represent meanS.E. of six observations from two
independent experiments. CTRL, control.
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DITPA on the 15-min uptake of [125I]T3, expressed as
fmol/pM free T3. T3 itself resulted in a clear dose-
dependent inhibition, and the maximum effect was seen
with 10 µM (45%; P<0·01) (Fig. 3A). T4 showed a
dose-dependent inhibition, but the maximum effect
at 10 µM (27%) was not significant (Fig. 3B). Exposure
to Triac did not result in reduction of [125I]T3 uptake
(Fig. 3C), whereas DITPA showed a stepwise reduction
with increasing concentrations (Fig. 3D), but the maxi-
mum effect was now 20% (NS), as compared with 28% in
Fig. 2.
The effects of a number of metabolites tested at
a concentration of 10 µM on [125I]T3 uptake at 15 min
(Fig. 4A) and 24 h (Fig. 4B) of incubation are shown in
Fig. 4. The uptake curve for [125I]T3 increased up to 4 h
of incubation and reached equilibrium between 4 and
24 h. Under control conditions, [125I]T3 uptake at 15 min,
1 h, 4 h and 24 h was 0·0890·017 (n=9), 0·2220·017
(n=9), 0·4330·038 (n=9) and 0·3520·038 (n=9)
fmol/pM free T3 respectively. After 15 min, [
125I]T3
uptake was inhibited by 52% (n=9; P<0·001) in the
presence of 10 µM 3,3-T2, and by 17% (n=9; NS) in the
presence of 10 µM 3,5-T2, whereas 10 µM Triac or Tetrac
had no effect at all (both n=9; NS). After 24 h of
incubation, the relative effect of 3,3-T2 was less (26%,
n=9; P<0·02) than that observed after 15 min of incu-
bation, whereas the effects of 3,5-T2 (13%), Triac and
Tetrac (both 19%) were still not significant. The effects of
10 µM unlabeled T3 are given for comparison, and
amounted to 52% (P<0·001) and 63% (P<0·001) after
15 min and 24 h respectively.
Presence of DITPA and T3 during culture
A second approach to evaluate possible effects of DITPA
on the T3 uptake system was to add 10 nM DITPA during
culture for 5 days and compare its effect with the presence
Figure 3 Competitive effects of unlabeled T3, T4, Triac and DITPA
on the 15-min uptake of [125I]T3 in cardiomyocytes. The cells were
cultured, preincubated and incubated with [125I]T3 as described in
the legend to Fig. 1, with increasing concentrations (1 nM–10 M)
of the unlabeled compounds present during incubation. Data are
expressed as fmol/pM free T3. Bars represent meanS.E. of nine
observations from three independent experiments. ctrl, control.
Figure 4 Effects of thyroid hormone metabolites on [125I]T3 uptake
in cardiomyocytes at 15 min (A) and 24 h (B) of incubation. The
cells were cultured, preincubated and incubated with [125I]T3 as
described in the legend to Fig. 1, with 10 M of the unlabeled
metabolites present during incubation. Data are expressed as
fmol/pM free T3. Bars represent meanS.E. of nine observations
from three independent experiments. Significant differences:
*P<0·001, **P<0·02 compared with controls (CTRL).
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of 10 nM T3. This experiment was performed twice and,
after culture, the time course of [125I]T3 uptake was tested
for from 15 min to 24 h in the absence or presence of
10 µM unlabeled T3 (Fig. 5). The time-course of [
125I]T3
uptake in the presence of 10 µM unlabeled T3 was about
the same in the three culture conditions (compare Fig. 5A,
B and C, lower curves). However, uptake of [125I]T3
without additions during incubation was significantly
greater in cells that had been cultured under control
conditions (Fig. 5A) than in cells that had been cultured in
the presence of 10 nM T3 (Fig. 5B) or DITPA (Fig. 5C).
Whereas the absolute reduction in T3 uptake by 10 µM
unlabeled T3 after 24 h of incubation was 2·01% of the
dose (42% inhibition; P<0·001) in the cells cultured under
control conditions, this was only 0·44% and 0·47% of the
dose (12% inhibition; NS) in cells cultured in the presence
of 10 nM T3 or DITPA. The protein content per well
under the different culture conditions was the same.
Discussion
In the present study, we explored further the uptake
mechanism for T3 in heart by comparing uptake of
[125I]T3 with that of [
125I]Triac and by testing the effects
of thyroid hormone metabolites and the analog DITPA on
T3 uptake in neonatal rat cardiomyocytes. Our previous
studies showed that T3 uptake in neonatal heart occurred
by a temperature- and energy-dependent mechanism that
was slightly dependent on the Na+ gradient (Everts et al.
1996b, Van der Putten et al. 2001), and sensitive to Ca2+
blockers (Verhoeven et al. 2001), whereas results for T4
uptake were less clear. The effects of the Ca2+ channel
inhibitors were not secondary to inhibition of Ca2+ influx,
suggesting interference with the putative T3 carrier in the
plasma membrane, rather than an energetic linkage to
effects of T3 on ion channels (Verhoeven et al. 2001).
Comparison of the time-courses of T3 and Triac uptake
in neonatal rat cardiomyocytes showed that, when ex-
pressed as fmol/pM free hormone, Triac uptake was about
30% greater than that of T3, but the difference was not as
large as in cultured pituitary cells, in which an almost
twofold difference was found (Everts et al. 1994). When
the 2-h cellular uptakes of T3 and Triac were measured
and expressed as percentages of the doses, a fivefold greater
value for T3 was observed, whereas the relative inhibition
by 10 µM of the respective unlabeled hormone was
roughly the same. Together, these findings indicate that
Triac is taken up by cardiomyocytes and bound to their
nuclear receptors, as in pituitary cells (Everts et al. 1994).
In contrast to pituitary cells, in which T3 uptake was
inhibited by Triac and vice versa (Everts et al. 1994), the
15-min T3 uptake in cardiomyocytes was not significantly
inhibited by increasing concentrations of Triac. As T3 and
T4 are scarcely metabolized by deiodination or conjugation
in neonatal cultured cardiomyocytes within 24 h (Everts
et al. 1996b), we extended the incubation periods to test
the various analogs up to 24 h. However, even after 24 h
of incubation, we could not detect any inhibitory effect of
10 µM Triac, suggesting different transport mechanisms
for T3 and Triac in heart. Addition of Triac to the diet of
rats induced an increase in oxygen consumption and heart
Figure 5 Time-course of [125I]T3 uptake in the absence () or
presence () of 10 M unlabeled T3 in rat cardiomyocytes
cultured without additions (A), with 10 nM T3 present (B) or with
10 nM DITPA present (C). Data are expressed as % dose, and
represent meanS.E. of six to 12 observations from two
independent experiments.
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rate, roughly to the same extent as addition of D-T3 (Boyd
& Oliver 1960). In contrast, neither Triac nor D-T3
acutely stimulated Na+ currents in cardiomyocytes
(Huang et al. 1999). Tetrac 10 µM reduced neither the
plasma membrane uptake of T3 at 15 min, or its cellular
uptake after 24 h. This is clearly at variance with the
findings in pituitary cells, in which Triac and Tetrac
inhibited [125I]T3 uptake over the range 15 min–4 h to
the same extent as unlabeled T3, and both suppressed
thyrotropin releasing hormone (TRH)-stimulated TSH
release (Everts et al. 1994, 1995). Tetrac has also been
reported to be more effective than T4 in suppressing TSH
secretion in vivo in hypothyroid rats (Lameloise et al. 2001),
whereas it was less effective in inducing cardiac hyper-
trophy. In our study, the inhibitory effect of T4 (around
25%) on T3 uptake was, if anything, greater than that of
Tetrac, albeit not significantly so.
Of the two other metabolites tested, 3,3-T2 signifi-
cantly reduced T3 uptake in cardiomyocytes, the effect
after 15 min (52% inhibition) being twice as large as that
after 24 h (26% inhibition), suggesting that 3,3-T2 pri-
marily interacted at the level of the plasma membrane.
The other diiodothyronine, 3,5-T2, had no effect on T3
uptake in heart cells between 15 min and 24 h of incu-
bation. Interestingly, 3,5-T2 has been shown to be more
effective than 3,3-T2 in suppressing TRH-induced TSH
release in pituitary cells (Everts et al. 1995). It is also
regarded as the important diiodothyronine with respect to
(direct) stimulation of heat production in mitochondria
(Goglia et al. 1999), and is just as effective as T3 in acutely
stimulating Na+ currents in neonatal rat cardiomyocytes
(Huang et al. 1999).
Because of its possible preferential effect on myocardial
contractility, the analog DITPA has been used, with the
purpose of improving heart function after infarction, but
so far only in animal studies (Pennock et al. 1993, 2000,
Morkin et al. 1996, Spooner et al. 1999). It has been shown
that DITPA binds to bacterially expressed thyroid hor-
mone receptors (Morkin et al. 1996). At the cellular level,
DITPA induces sarcoplasmic reticulum Ca2+ transport and
protein expression (Pennock et al. 2000), but interpret-
ation of data on changes in myosin heavy-chain isoenzyme
has been more complicated (Spooner et al. 1999). From
this point of view, there remains a lack of understanding of
how DITPA works (Spooner et al. 1999). In the present
study, DITPA was tested for effects on T3 uptake in
cardiomyocytes. Up to a concentration of 10 µM, DITPA
had a less clear effect on the 15-min T3 uptake (20–28%)
as compared with 10 µM T3 itself (46–52%). In contrast,
the effect of 10 µM DITPA after 4 h of incubation was at
least as great (56%) as that of unlabeled T3 (42–63%;
compare Figs 2 and 5A), suggesting that DITPA can bind
to the cytosolic or nuclear T3 binding sites of the cardio-
myocytes. When DITPA was added during culture at a
concentration of 10 nM, its effect was comparable to that
of the same concentration of T3: the inhibitory effect of
10 µM T3 on cellular T3 uptake at 24 h was only 12%,
whereas it was 42% in cells cultured under control
conditions. As we have not tested whether DITPA inter-
acts with the nuclear T3 receptors, it is difficult to
conclude whether DITPA primarily interferes with plasma
membrane T3 transport or with cytosolic or nuclear T3
binding. To what extent the inhibitory effect of DITPA
on T3 uptake in the cardiomyocyte results in attenuation
or stimulation of thyromimetic effects, for example on
expression of the Na+,K+-ATPase isoforms, is currently
being investigated.
The aromatic amino acid, tyrosine, the precursor of
iodothyronines, and tryptophan share the same transport
system (Christensen 1990). In two studies with cardio-
myocytes, we reported that tryptophan in concentrations
of 0·5 and 2 mM significantly reduced T3 uptake (maxi-
mum response 30–45%; Everts et al. 1996b, Van der
Putten et al. 2001). Moreover, the effects of tryptophan
were additive to those of oligomycin, an inhibitor of
oxidative phosphorylation, suggesting that at least two
different transport systems may be responsible for T3
uptake in neonatal heart (Van der Putten et al. 2001). One
could be a transport system that is capable of transporting
aromatic amino acids. Kragie (1994) and Hennemann et al.
(2001) have reviewed the properties of thyroid hormone
transport mechanisms in many cell types. We have pre-
viously compared uptake mechanisms for thyroid hor-
mones in pituitary and liver, and postulated that regulation
of the transport in these two tissues was different (Everts
et al. 1996a). This difference could play a part in main-
tenance of the low serum T3 and normal TSH concen-
trations in non-thyroidal illness and fasting (Everts et al.
1996a, Hennemann et al. 1998, 2001). When the present
data are compared with the results obtained in pituitary
cells (Everts et al. 1994, 1995), it seems that the transport
mechanism for T3 into the heart is different. Whether T3
uptake in heart is similar or different as compared with that
in liver (Everts et al. 1996a) remains to be established. This
question is of relevance to the development of drugs with
tissue-selective thyromimetic activity (Ichikawa et al.
2000, Trost et al. 2000).
Conclusion
3,3-T2, and to a lesser extent DITPA and T4, inhibit
plasma membrane T3 uptake in the cardiomyocyte,
whereas 3,5-T2, Triac and Tetrac have no significant
effects. In contrast, Triac itself is taken up by the cardio-
myocyte, but probably through a transport mechanism
other than that for T3. Our current research plan includes
investigation of whether exposure of cardiomyocytes to
Triac and DITPA results in thyromimetic effects, and
whether exposure to compounds that inhibit T3 transport
(in particular 3,3-T2) results in reduction of T3-induced
effects in the cardiomyocyte.
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